BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3242Biotechnology
$18.00 +$0.14 (+0.78%)
Pre-market · Oct 8, 8:50 am ET · After hours $18.00 0.00%
Open$17.72
Prev close$17.86
Day range$17.70 – $18.35
Volume294.1K
Market cap$1.00B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-13.2x
CheapRich

Near the top of its 5-year range · 97th percentile, 5-year average -17.3x

Price / book2.1x
CheapRich

Around its usual level · 49th percentile, 5-year average -1.9x

#2989 of 5317 stocks by PB (1 = cheapest)

Price / sales99.5x
CheapRich

Near the bottom of its 5-year range · 3rd percentile, 5-year average 156.8x

#4925 of 5146 stocks by PS (1 = cheapest)

P/E over five years

-29x-18x-8x2xJan '26May '26Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$29.13
Price vs. fair value-38.2%Trading below the estimate
Star rating★★★★★
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.06 – -1.94 49% (cheaper than usual) #2989 of 5317 (1 = cheapest)
PE -13.16 -8.05 -17.32 97% (pricier than usual) –
PS 99.52 130.56 156.76 3% (cheaper than usual) #4925 of 5146 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★★★
Fair value estimate$29.13
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on AKTS.

Leave a comment

Scroll to Top